Lutz Gieselmann

TL;DR: The on-going presence of either shortness of breath, anosmia, ageusia or fatigue as long-lasting symptoms even in non-hospitalised patients was observed at four and seven months post-infection and summarised as post-COVID syndrome (PCS).

TL;DR: It is demonstrated that SARS-CoV-2-neutralizing antibodies are readily generated from a diverse pool of precursors, fostering hope for rapid induction of a protective immune response upon vaccination.

TL;DR: In this article, the authors evaluated SARS-CoV-2 antibody dynamics over 10 months in 963 individuals who predominantly experienced mild COVID-19 and found that approximately 3% of individuals demonstrated exceptional SARSCoV2 neutralization, with these "elite neutralizers" also possessing SARS CoV-1 cross-neutralizing IgG.

TL;DR: The humoral immune response in a subset of human volunteers enrolled in a phase 1 rVSV-ZEBOV vaccination trial is examined by performing comprehensive single B cell and electron microscopy structure analyses, and highly potent EBOV-neutralizing antibodies with activities comparable or superior to the monoclonal antibodies currently used in clinical trials are detected.

TL;DR: A broad spectrum of the initial SARS-CoV-2 neutralizing antibody response depending on clinical characteristics is demonstrated, with antibodies being maintained in the majority of individuals for the first 10 months after mild course of COVID-19.